<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK190102" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK190102/" /><meta name="ncbi_pagename" content="EPB42-Related Hereditary Spherocytosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>EPB42-Related Hereditary Spherocytosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="EPB42-Related Hereditary Spherocytosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2016/11/10" /><meta name="citation_author" content="Theodosia A Kalfa" /><meta name="citation_author" content="Jessica A Connor" /><meta name="citation_author" content="Amber H Begtrup" /><meta name="citation_pmid" content="24624460" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK190102/" /><meta name="citation_keywords" content="Erythrocyte membrane protein band 4.2" /><meta name="citation_keywords" content="EPB42" /><meta name="citation_keywords" content="EPB42-Related Hereditary Spherocytosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="EPB42-Related Hereditary Spherocytosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Theodosia A Kalfa" /><meta name="DC.Contributor" content="Jessica A Connor" /><meta name="DC.Contributor" content="Amber H Begtrup" /><meta name="DC.Date" content="2016/11/10" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK190102/" /><meta name="description" content="EPB42-related hereditary spherocytosis (EPB42-HS) is a chronic non-immune hemolytic anemia that is usually of mild to moderate severity. EPB42-HS can present with jaundice as early as the first 24 hours of life or can present later in childhood with anemia resulting from a hemolytic crisis or aplastic crisis (usually associated with a viral infection). In addition to the hematologic manifestations, serious complications include splenomegaly that can become evident in early childhood and cholelithiasis that usually becomes evident in the second or third decade of life." /><meta name="og:title" content="EPB42-Related Hereditary Spherocytosis" /><meta name="og:type" content="book" /><meta name="og:description" content="EPB42-related hereditary spherocytosis (EPB42-HS) is a chronic non-immune hemolytic anemia that is usually of mild to moderate severity. EPB42-HS can present with jaundice as early as the first 24 hours of life or can present later in childhood with anemia resulting from a hemolytic crisis or aplastic crisis (usually associated with a viral infection). In addition to the hematologic manifestations, serious complications include splenomegaly that can become evident in early childhood and cholelithiasis that usually becomes evident in the second or third decade of life." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK190102/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/epb42-spherocytosis/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK190102/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88EC31E040CD5100000000017D008F.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK190102_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK190102_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cyclic-n/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/exosc3-pc-hypo-p/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK190102_"><span class="title" itemprop="name"><i>EPB42</i>-Related Hereditary Spherocytosis</span></h1><p class="contrib-group"><span itemprop="author">Theodosia A Kalfa</span>, MD, PhD, <span itemprop="author">Jessica A Connor</span>, MS, and <span itemprop="author">Amber H Begtrup</span>, PhD, FACMG.</p><a data-jig="ncbitoggler" href="#__NBK190102_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK190102_ai__"><div class="contrib half_rhythm"><span itemprop="author">Theodosia A Kalfa</span>, MD, PhD<div class="affiliation small">Cancer and Blood Diseases Institute<br />Division of Hematology<br />Cincinnati Children's Hospital Medical Center and University of Cincinnati Medical School<br />Cincinnati, Ohio<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cmhcc@aflak.aisodoeht" class="oemail">gro.cmhcc@aflak.aisodoeht</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Jessica A Connor</span>, MS<div class="affiliation small">Counsyl, Inc<br />South San Francisco, California<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.lysnuoc@ronnocj" class="oemail">moc.lysnuoc@ronnocj</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Amber H Begtrup</span>, PhD, FACMG<div class="affiliation small">GeneDx, Inc<br />Gaithersburg, Maryland<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.xdeneg@purtgeba" class="oemail">moc.xdeneg@purtgeba</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">March 13, 2014</span>; Last Update: <span itemprop="dateModified">November 10, 2016</span>.</p><p><em>Estimated reading time: 23 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="epb42-spherocytosis.Summary" itemprop="description"><h2 id="_epb42-spherocytosis_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p><i>EPB42</i>-related hereditary spherocytosis (EPB42-HS) is a chronic non-immune hemolytic anemia that is usually of mild to moderate severity. EPB42-HS can present with jaundice as early as the first 24 hours of life or can present later in childhood with anemia resulting from a hemolytic crisis or aplastic crisis (usually associated with a viral infection). In addition to the hematologic manifestations, serious complications include splenomegaly that can become evident in early childhood and cholelithiasis that usually becomes evident in the second or third decade of life.</p><p>Typical laboratory findings in EPB42-HS include anemia (decreased hemoglobin [Hgb] level) and reticulocytosis (increased percent of reticulocytes), with high mean corpuscular hemoglobin concentration (MCHC), presence of spherocytes in the peripheral blood smear, significantly decreased or absent haptoglobin, mildly increased osmotic fragility, and decreased maximal deformability index (DI<sub>max</sub>) with increased O<sub>min</sub> (osmolality at which 50% of red blood cells hemolyze) measured by ektacytometry.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of EPB42-HS is established by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>EPB42</i>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment for mild EPB42-HS (Hgb 11-15 g/dL, reticulocytes 3%-8%) includes folic acid supplementation (400 &#x000b5;g 1x daily until age 1 year; 1 mg 1x daily thereafter) and RBC transfusion as needed for a hemolytic or aplastic crisis. Although splenectomy is rarely indicated in EPB42-HS since disease severity is usually mild or moderate, it may be recommended in those with moderately severe EPB42-HS (Hgb 6-8 g/dL, reticulocytes &#x02265;10%) who are older than age five years when quality of life is compromised. Although curative, splenectomy entails a long-term increased risk for potential life-threatening infection, and thus requires complete immunizations before the procedure and antibiotic prophylaxis after. Affected individuals with a history of cholelithiasis should have cholecystectomy at the time of splenectomy.</p><p><i>Prevention of primary manifestations:</i> See <i>Treatment of manifestations</i> for information on use of splenectomy.</p><p><i>Prevention of secondary complications:</i> Regular immunizations to prevent infections that can trigger a hemolytic or aplastic crisis. Iron overload is a risk especially if frequent transfusions are required; treatment with an iron chelator is typically begun after about ten transfusions (which correlate to a serum ferritin concentration of approximately 1,000 ng/mL).</p><p><i>Surveillance:</i> Neonates require monitoring of serum bilirubin concentration during the first week of life and infants require monitoring of Hgb in the first two to four months of life to screen for significant anemia. Those dependent on frequent transfusions and those receiving iron chelation therapy require monitoring of serum ferritin concentration. Abdominal ultrasound examination to evaluate for cholelithiasis either when symptoms are present or, when hemolysis is significant, by age ten to 12 years, and every five to ten years thereafter.</p><p><i>Agents/circumstances to avoid:</i> Any preparations containing iron; however, if iron studies have documented iron deficiency, treatment with supplemental iron must be closely monitored and then discontinued when iron stores have been repleted. Avoidance of contact sports is recommended in those with splenomegaly; of note, acute or excessive splenomegaly is a greater risk than chronic mild splenomegaly.</p><p><i>Evaluation of relatives at risk:</i> When EPB42-HS has been diagnosed in a family member, the following is recommended for at-risk sibs: (1) Neonates at risk require monitoring of serum bilirubin concentration during the first week of life so that treatment for hyperbilirubinemia can be instituted promptly; and (2) infants at risk require monitoring in the first two to four months of life for significant anemia, which may require RBC transfusion and initiation of folate supplementation. Laboratory evaluation (CBC and reticulocyte count, blood smear, osmotic fragility or ektacytometry) and/or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> for the <i>EPB42</i> pathogenic variants in the family (if known) is appropriate for at-risk relatives.</p><p><i>Pregnancy management:</i> Folic acid supplementation (800-1,000 &#x000b5;g daily) is necessary; monitoring for exacerbation of anemia with CBC and reticulocyte count is recommended.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>EPB42-HS is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the pathogenic variants in the family have been identified.</p></div></div><div id="epb42-spherocytosis.Diagnosis"><h2 id="_epb42-spherocytosis_Diagnosis_">Diagnosis</h2><div id="epb42-spherocytosis.Suggestive_Findings"><h3>Suggestive Findings</h3><p><i>EPB42</i>-related hereditary spherocytosis (EPB42-HS) <b>should be suspected</b> in individuals with any of the following clinical and supportive laboratory findings:</p><p><b>Clinical findings</b></p><ul><li class="half_rhythm"><div>Pallor and/or fatigue due to anemia, which is usually of mild to moderate severity</div></li><li class="half_rhythm"><div>Jaundice</div><ul><li class="half_rhythm"><div>Usually intermittent and caused by unconjugated hyperbilirubinemia resulting from exacerbated hemolysis</div></li><li class="half_rhythm"><div>In rare cases, caused by conjugated hyperbilirubinemia resulting from biliary obstruction</div></li></ul></li><li class="half_rhythm"><div>Splenomegaly</div></li><li class="half_rhythm"><div>Cholelithiasis in the second or third decade of life</div></li><li class="half_rhythm"><div>Family history consistent with <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> inheritance</div><div>Note: Absence of a family history of EPB42-HS does not preclude the diagnosis.</div></li></ul><p><b>Supportive laboratory findings</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Complete blood count</b> consistent with:</div><ul><li class="half_rhythm"><div>Chronic, non-immune hemolytic anemia (decreased hemoglobin with reticulocytosis), usually of mild to moderate severity</div><ul><li class="half_rhythm"><div class="half_rhythm">Decreased hemoglobin (Hgb) level (See <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.severity_of_heredi/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTseverityofheredi" rid-ob="figobepb42spherocytosisTseverityofheredi">Table 1</a> for Hgb levels that define the severity of hereditary spherocytosis.)</div><div class="half_rhythm">Note: Hgb values in EPB42-HS may also vary depending on the clinical status of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual (baseline or during a hemolytic or aplastic crisis).</div></li><li class="half_rhythm"><div class="half_rhythm">Increased percent of reticulocytes as well as increased absolute reticulocyte count (ARC) (See <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.severity_of_heredi/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTseverityofheredi" rid-ob="figobepb42spherocytosisTseverityofheredi">Table 1</a> for percent of reticulocytes that define the severity of hereditary spherocytosis.)</div><div class="half_rhythm">Note: Percent of reticulocytes may vary (depending on baseline or crisis status) from 2.5 to greater than 10% (or even normal or low when in aplastic crisis).</div></li></ul></li><li class="half_rhythm"><div>High mean corpuscular hemoglobin concentration (MCHC). Normal values are typically 31-37 g/dL. Values in HS are usually 35.5-37.5 g/dL.</div></li></ul></li><li class="half_rhythm"><div class="half_rhythm"><b>Negative (i.e., normal) direct anti-globulin test (DAT)</b></div><div class="half_rhythm">Note: DAT should always be evaluated in a person with newly diagnosed hemolytic anemia to evaluate for an acute immune-mediated (acquired) hemolytic anemia.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Peripheral blood smear</b> demonstrating presence of spherocytes and occasionally a few ovalocytes and elliptocytes</div><div class="half_rhythm">Note: The term spherocyte refers to the sphere-shaped red blood cells (with a decreased surface/volume ratio) that characterize the RBC cytoskeleton disorders (see <a href="#epb42-spherocytosis.Differential_Diagnos">Differential Diagnosis</a>).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Significantly decreased or absent haptoglobin.</b> After age six months normal haptoglobin values are 16-200 mg/dL. In HS, haptoglobin is typically undetectable; however, haptoglobin can be normal in the presence of concurrent inflammation (as it is an acute phase reactant).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Mildly increased osmotic fragility</b> (as in <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3105174/figure/F1/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Figure 1B</a> of <a class="bk_pop" href="#epb42-spherocytosis.REF.hammill.2011.780">Hammill et al [2011]</a>; see <a href="/pmc/articles/PMC3105174/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>)</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Decreased maximal deformability index (DI<sub>max</sub>)</b> and <b>increased O<sub>min</sub></b> (osmolality at which 50% of red blood cells hemolyze) measured by ektacytometry, giving a typical HS curve [<a class="bk_pop" href="#epb42-spherocytosis.REF.clark.1983.899">Clark et al 1983</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</a>]</div></li></ul><div id="epb42-spherocytosis.T.severity_of_heredi" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Severity of Hereditary Spherocytosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK190102/table/epb42-spherocytosis.T.severity_of_heredi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epb42-spherocytosis.T.severity_of_heredi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severity</th><th id="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hgb (g/dL)</th><th id="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reticulocytes (%)</th><th id="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Splenectomy</th></tr></thead><tbody><tr><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Mild</b></td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11-15</td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">3-8</td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Not necessary</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Moderate</b></td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8-11.5</td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003e;8</td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Consider if activity level &#x00026; quality of life are decreased</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Moderately severe</b></td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6-8</td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02265;10</td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Indicated at age &#x0003e;5 yrs</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Severe</b></td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;6</td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x02265;10</td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Indicated at age &#x0003e;3 yrs</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Normal&#x000a0;<sup>1</sup></b></td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11.7-15.7 (adult females) 13.3-17.7 (adult males)</td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">0.5-1.5&#x000a0;<sup>2</sup></td><td headers="hd_h_epb42-spherocytosis.T.severity_of_heredi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Based on table by <a class="bk_pop" href="#epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux [2004]</a></p></div></dd><dt>1. </dt><dd><div id="epb42-spherocytosis.TF.1.1"><p class="no_margin">Normal values may vary somewhat depending on age and gender.</p></div></dd><dt>2. </dt><dd><div id="epb42-spherocytosis.TF.1.2"><p class="no_margin">ARC 45-90 x 10<sup>3</sup>/&#x000b5;L</p></div></dd></dl></div></div></div></div><div id="epb42-spherocytosis.Establishing_the_Dia"><h3>Establishing the Diagnosis</h3><p>The diagnosis of <i>EPB42</i>-related hereditary spherocytosis <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by the identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>EPB42</i> (see <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.molecular_genetic/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTmoleculargenetic" rid-ob="figobepb42spherocytosisTmoleculargenetic">Table 2</a>).</p><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>EPB42</i> is performed.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>EPB42</i> and other genes of interest (see <a href="#epb42-spherocytosis.Differential_Diagnos">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><div id="epb42-spherocytosis.T.molecular_genetic" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in <i>EPB42</i>-Related Hereditary Spherocytosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK190102/table/epb42-spherocytosis.T.molecular_genetic/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epb42-spherocytosis.T.molecular_genetic_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>EPB42</i></td><td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">16/16&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_epb42-spherocytosis.T.molecular_genetic_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown&#x000a0;<sup>6,&#x000a0;7</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="epb42-spherocytosis.TF.2.1"><p class="no_margin">See <a href="/books/NBK190102/#epb42-spherocytosis.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="epb42-spherocytosis.TF.2.2"><p class="no_margin">See <a href="#epb42-spherocytosis.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="epb42-spherocytosis.TF.2.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="epb42-spherocytosis.TF.2.4"><p class="no_margin">Most are case reports with no information on the number of individuals with hereditary spherocytosis who did not have pathogenic variants identified in <i>EPB42</i> [<a class="bk_pop" href="#epb42-spherocytosis.REF.kanzaki.1997.522">Kanzaki et al 1997</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.toye.2008.5380">Toye et al 2008</a>].</p></div></dd><dt>5. </dt><dd><div id="epb42-spherocytosis.TF.2.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods that may be used include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="epb42-spherocytosis.TF.2.6"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd><dt>7. </dt><dd><div id="epb42-spherocytosis.TF.2.7"><p class="no_margin">The only gross <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> reported to date is a 32-<a class="def" href="/books/n/gene/glossary/def-item/base-pair/">base pair</a> deletion [<a class="bk_pop" href="#epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</a>] that is expected to be detectable by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</p></div></dd></dl></div></div></div></div></div><div id="epb42-spherocytosis.Clinical_Characteris"><h2 id="_epb42-spherocytosis_Clinical_Characteris_">Clinical Characteristics</h2><div id="epb42-spherocytosis.Clinical_Description"><h3>Clinical Description</h3><p>Children with <i>EPB42</i>-related hereditary spherocytosis (EPB42-HS) frequently present within the first 24 hours of life with jaundice that requires treatment with phototherapy or, rarely, exchange transfusion to prevent kernicterus. They may also present later in childhood with anemia resulting from a hemolytic crisis or aplastic crisis usually associated with a viral infection.</p><p>Toddlers with hereditary spherocytosis are occasionally found to have age-related iron deficiency anemia; however, the anemia fails to completely resolve with iron supplementation and reticulocytosis persists.</p><p>As with all forms of mild or moderate hereditary spherocytosis (see <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.severity_of_heredi/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTseverityofheredi" rid-ob="figobepb42spherocytosisTseverityofheredi">Table 1</a> for definitions), EPB42-HS can be more severe in the first four to six months of life, requiring regular red blood cell transfusions. Thus, frequent transfusions during the first few months of life do not necessarily correlate with disease severity later on.</p><p>EPB42-HS, if not recognized during infancy or early childhood, may be diagnosed later in life as a mild (Hgb 11-15 g/dL) to moderate (Hgb 8-11.5 g/dL) chronic hemolytic anemia (see <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.severity_of_heredi/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTseverityofheredi" rid-ob="figobepb42spherocytosisTseverityofheredi">Table 1</a>), with jaundice, splenomegaly, and cholelithiasis at a relatively young age [<a class="bk_pop" href="#epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</a>].</p></div><div id="epb42-spherocytosis.GenotypePhenotype_Co"><h3>Genotype-Phenotype Correlations</h3><p>Homozygosity for <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Ala142Thr</a> has been found most commonly in Japan and was reported to lead to moderately severe HS, with Hgb as low as 6.1 g/dL [<a class="bk_pop" href="#epb42-spherocytosis.REF.bouhassira.1992.1846">Bouhassira et al 1992</a>]. A non-Japanese <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual with the same <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> was reported in Italy; her <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> included moderate hemolytic anemia from birth and splenomegaly [<a class="bk_pop" href="#epb42-spherocytosis.REF.perrotta.1999.660">Perrotta et al 1999</a>].</p><p>Homozygosity for <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Ala142Thr</a> or homozygosity for <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Asp175Tyr</a> results in atypical HS with the presence of ovalostomatocytes in addition to few spherocytes in the blood smear. Hemolysis may be mild to moderately severe and improves after splenectomy [<a class="bk_pop" href="#epb42-spherocytosis.REF.bouhassira.1992.1846">Bouhassira et al 1992</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.kanzaki.1995.165">Kanzaki et al 1995</a>].</p><p>Compound heterozygosity for <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Ala142Thr</a> with another <i>EPB42</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> causes typical HS with microspherocytes in the blood smear and increased osmotic fragility [<a class="bk_pop" href="#epb42-spherocytosis.REF.takaoka.1994.527">Takaoka et al 1994</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.kanzaki.1995.165">Kanzaki et al 1995</a>]. Case reports of individuals with other <i>EPB42</i> pathogenic variants also indicate mild to moderate HS with only occasional need for blood transfusion [<a class="bk_pop" href="#epb42-spherocytosis.REF.hayette.1995.250">Hayette et al 1995</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.van_den_akker.2010.1278">van den Akker et al 2010</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</a>].</p><p>One individual <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for the <a class="def" href="/books/n/gene/glossary/def-item/null/">null</a> <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">c.950delG</a> variant (resulting in premature termination of the transcript and lack of production of any viable erythrocyte membrane protein band 4.2 &#x02013; known in recent literature as protein 4.2) developed a strong antibody response against protein 4.2 after multiple red blood cell transfusions for gastrointestinal bleeding, causing alloimmune hemolytic anemia [<a class="bk_pop" href="#epb42-spherocytosis.REF.beauchampnicoud.2000.19">Beauchamp-Nicoud et al 2000</a>]. Antibody development has not been described yet following red blood cell transfusion in persons with other <i>EPB42</i> pathogenic variants, although in most of the cases of <i>EPB42</i>-associated HS no protein 4.2 is detectable in the RBC membrane [<a class="bk_pop" href="#epb42-spherocytosis.REF.satchwell.2009.201">Satchwell et al 2009</a>].</p></div><div id="epb42-spherocytosis.Prevalence"><h3>Prevalence</h3><p>Hereditary spherocytosis is the most common inherited anemia in individuals of northern European ancestry, with a prevalence of 1:2000 or higher when the very mild forms (which are frequently underdiagnosed) are included. The worldwide prevalence is lower.</p><p><i>EPB42</i>-associated hereditary spherocytosis is responsible for 40%-50% of hereditary spherocytosis in Japan, where the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Ala142Thr</a> among healthy persons is as high as 3% [<a class="bk_pop" href="#epb42-spherocytosis.REF.yawata.1994.131">Yawata 1994</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.yawata.2000.118">Yawata et al 2000</a>].</p><p>In other populations, EPB42-HS accounts for 5% or less of HS [<a class="bk_pop" href="#epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.perrotta.2008.1411">Perrotta et al 2008</a>].</p></div></div><div id="epb42-spherocytosis.Genetically_Related"><h2 id="_epb42-spherocytosis_Genetically_Related_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>EPB42.</i></p></div><div id="epb42-spherocytosis.Differential_Diagnos"><h2 id="_epb42-spherocytosis_Differential_Diagnos_">Differential Diagnosis</h2><p>The initial evaluation of a person with hemolytic anemia typically includes: complete blood count (CBC) and reticulocyte count; blood smear review; direct anti-globulin test (DAT) and indirect Coombs to evaluate for auto-immune (or, in an infant, allo-immune) hemolytic anemia; hemoglobin electrophoresis; and G6PD enzyme activity (especially in males). Osmotic fragility testing and/or ektacytometry can focus the diagnosis within an erythrocyte membrane disorder. <a class="figpopup" href="/books/NBK190102/figure/epb42-spherocytosis.F1/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisF1" rid-ob="figobepb42spherocytosisF1">Figure 1</a> demonstrates ektacytometry results typical of hereditary spherocytosis. Classification of hereditary spherocytosis based on genetic etiology is shown in <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.classification_of/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTclassificationof" rid-ob="figobepb42spherocytosisTclassificationof">Table 3</a>.</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figepb42spherocytosisF1" co-legend-rid="figlgndepb42spherocytosisF1"><a href="/books/NBK190102/figure/epb42-spherocytosis.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="figepb42spherocytosisF1" rid-ob="figobepb42spherocytosisF1"><img class="small-thumb" src="/books/NBK190102/bin/epb42-spherocytosis-Image001.gif" src-large="/books/NBK190102/bin/epb42-spherocytosis-Image001.jpg" alt="Figure 1. . Ektacytometry indicating a typical curve for HS (red), characterized by increased Omin and decreased EImax and Ohyp in comparison to normal control (blue)." /></a><div class="icnblk_cntnt" id="figlgndepb42spherocytosisF1"><h4 id="epb42-spherocytosis.F1"><a href="/books/NBK190102/figure/epb42-spherocytosis.F1/?report=objectonly" target="object" rid-ob="figobepb42spherocytosisF1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">Ektacytometry indicating a typical curve for HS (red), characterized by increased O<sub>min</sub> and decreased EI<sub>max</sub> and O<sub>hyp</sub> in comparison to normal control (blue). O<sub>min</sub> corresponds to the osmolality where 50% of the cells hemolyze in the osmotic fragility test <a href="/books/NBK190102/figure/epb42-spherocytosis.F1/?report=objectonly" target="object" rid-ob="figobepb42spherocytosisF1">(more...)</a></p></div></div><p>For the individual with non-immune hemolytic anemia, the differential diagnosis includes the other causes of hereditary hemolytic anemia, including the other forms of hereditary spherocytosis:</p><ul><li class="half_rhythm"><div>Other RBC membrane disorders</div></li><li class="half_rhythm"><div>Hereditary spherocytosis (see <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.classification_of/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTclassificationof" rid-ob="figobepb42spherocytosisTclassificationof">Table 3</a>)</div></li><li class="half_rhythm"><div>Hereditary elliptocytosis, stomatocytosis, or Southeast Asian ovalocytosis, since individuals <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for either <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Ala142Thr</a> or <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Asp175Tyr</a> in <i>EPB42</i> are reported to also have ovalocytes and stomatocytes in the blood smear. Note: Splenectomy has been associated with significant and life-threatening thrombotic events in persons with hereditary stomatocytosis (overhydrated or dehydrated/xerocytosis); therefore, differentiation between hereditary stomatocytosis and <i>EPB42</i>-associated HS (EPB42-HS) is necessary if splenectomy is contemplated.</div></li><li class="half_rhythm"><div>Hemoglobin disorders. EPB42-HS is usually easily distinguished from <a href="/books/n/gene/b-thal/">&#x003b2;-thalassemia</a> or <a href="/books/n/gene/a-thal/">HbH disease</a>, both of which are characterized by microcytosis and hypochromia. Chronic mild hemolytic anemias due to unstable hemoglobin chains may require further evaluation, including hemoglobin analysis by electrophoresis or HPLC and/or globin <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> sequencing.</div></li><li class="half_rhythm"><div>Erythrocyte enzymopathies, such as glucose-6-phospate dehydrogenase (G6PD) deficiency (OMIM <a href="http://omim.org/entry/300908" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">300908</a>) or pyruvate kinase (PK) deficiency (OMIM <a href="http://omim.org/entry/266200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">266200</a>); typically distinguished from EPB42-HS by absence of spherocytic RBC morphology and by normal ektacytometry or osmotic fragility. Some erythrocyte enzyme disorders (e.g., triose phosphate isomerase [TPI] deficiency [OMIM <a href="http://omim.org/entry/615512" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">615512</a>] or phosphoglycerate kinase 1 [PGK1] deficiency [OMIM <a href="http://omim.org/entry/300653" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">300653</a>]) also have neurologic and musculoskeletal manifestations. Enzymatic activity assays and/or <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> sequencing establishes the diagnosis.</div></li><li class="half_rhythm"><div>Congenital dyserythropoietic anemia, especially type II when it presents with a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (i.e., mild anemia, reticulocytosis [although suboptimal], jaundice, and splenomegaly) (See <a href="/books/n/gene/cda1/">Congenital Dyserythropoietic Anemia Type I</a>.)</div></li></ul><div id="epb42-spherocytosis.T.classification_of" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Classification of Hereditary Spherocytosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK190102/table/epb42-spherocytosis.T.classification_of/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epb42-spherocytosis.T.classification_of_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Locus</th><th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene</th><th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protein</th><th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severity&#x000a0;<sup>1</sup></th><th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th><th id="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">OMIM</th></tr></thead><tbody><tr><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">SPH1</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><i>ANK1</i></td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Ankyrin-1</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild -moderate</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/182900" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">182900</a></td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Moderately severe -severe</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Often transfusion dependent</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">SPH2</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><i>SPTB</i></td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">Spectrin beta chain, erythrocytic</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild -moderate</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"></td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/616649" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">616649</a></td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 fatal infantile case described</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SPH3</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SPTA1</i></td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Spectrin alpha chain, erythrocytic 1</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Severe</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Transfusion dependent</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/270970" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">270970</a></td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SPH4</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SLC4A1</i></td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Band 3 (anion transport protein)</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild -moderate</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Certain <i>SLC4A1</i> pathogenic variants cause disease only when <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a>.</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/612653" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612653</a></td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">SPH5</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>EPB42</i></td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Protein 4.2&#x000a0;<sup>2</sup></td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mild -moderate&#x000a0;<sup>3</sup></td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1 moderately severe case described</td><td headers="hd_h_epb42-spherocytosis.T.classification_of_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="http://omim.org/entry/612690" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">612690</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a></p></div></dd><dt></dt><dd><div><p class="no_margin">AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a></p></div></dd><dt>1. </dt><dd><div id="epb42-spherocytosis.TF.3.1"><p class="no_margin">Defined in <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.severity_of_heredi/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTseverityofheredi" rid-ob="figobepb42spherocytosisTseverityofheredi">Table 1</a></p></div></dd><dt>2. </dt><dd><div id="epb42-spherocytosis.TF.3.2"><p class="no_margin">Significant decrease or absence of erythrocyte membrane protein band 4.2 (known in recent literature simply as protein 4.2) in erythrocytes of persons with HS may also be secondary to <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SLC4A1</i> pathogenic variants (SPH4) by either decreasing band 3 in the red blood cell membrane [<a class="bk_pop" href="#epb42-spherocytosis.REF.toye.2008.5380">Toye et al 2008</a>] or affecting the band 3 binding site for protein 4.2 [<a class="bk_pop" href="#epb42-spherocytosis.REF.kanzaki.1997.522">Kanzaki et al 1997</a>].</p></div></dd><dt>3. </dt><dd><div id="epb42-spherocytosis.TF.3.3"><p class="no_margin"><i>SPH5</i> is typically milder than the other forms of hereditary spherocytosis inherited in an AR manner (i.e., SPH1 [AR] and SPH3).</p></div></dd></dl></div></div></div></div><div id="epb42-spherocytosis.Management"><h2 id="_epb42-spherocytosis_Management_">Management</h2><div id="epb42-spherocytosis.Evaluations_Followin"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with <i>EPB42</i>-related hereditary spherocytosis (EPB42-HS), the following evaluations are recommended:</p><ul><li class="half_rhythm"><div>Hemoglobin concentration and reticulocyte count to evaluate severity of disease</div></li><li class="half_rhythm"><div>Serum bilirubin concentration</div></li><li class="half_rhythm"><div>Transfusion history</div></li><li class="half_rhythm"><div>Serum ferritin concentration to evaluate iron load status</div></li><li class="half_rhythm"><div>Abdominal ultrasound examination to evaluate:</div><ul><li class="half_rhythm"><div>Spleen size if physical examination is not conclusive due to body habitus or if contact sports are contemplated</div></li><li class="half_rhythm"><div>For evidence of cholelithiasis when symptoms are present. If hemolysis is significant a screening ultrasound may be considered after age 10-12 years, even without symptoms.</div></li></ul></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="epb42-spherocytosis.Treatment_of_Manifes"><h3>Treatment of Manifestations</h3><p>Detailed management <a href="#epb42-spherocytosis.References">guidelines</a> for hereditary spherocytosis (HS) have been published [<a class="bk_pop" href="#epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.boltonmaggs.2012">Bolton-Maggs et al 2012</a>].</p><p><b>Conservative management</b> recommendations for mild EPB42-HS (Hgb 11-15 g/dL, reticulocytes 3-8%) (<a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.severity_of_heredi/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTseverityofheredi" rid-ob="figobepb42spherocytosisTseverityofheredi">Table 1</a>) include the following:</p><ul><li class="half_rhythm"><div class="half_rhythm">Folic acid supplementation (400 &#x000b5;g 1x daily until age 1 year; then 1 mg 1x daily thereafter)</div></li><li class="half_rhythm"><div class="half_rhythm">Avoidance of iron supplementation unless concurrent iron deficiency is confirmed with iron studies, in which case treatment with supplemental iron should be carefully monitored and discontinued after iron stores are repleted to avoid iron overload</div><div class="half_rhythm">Note: Hereditary spherocytosis (as all chronic hemolytic anemias) involves an increased risk for iron overload even with oral iron supplementation (see <a href="#epb42-spherocytosis.Prevention_of_Second">Prevention of Secondary Complications</a>).</div></li><li class="half_rhythm"><div class="half_rhythm">Red blood cell (RBC) transfusion, if needed, for hemolytic or aplastic crisis</div></li></ul><p><b>Splenectomy</b> is rarely indicated in EPB42-HS, as disease severity is usually mild or moderate. However, when disease is moderate (see <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.severity_of_heredi/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTseverityofheredi" rid-ob="figobepb42spherocytosisTseverityofheredi">Table 1</a>) and normal activity or quality of life is compromised, splenectomy can be performed after age five years provided that hereditary stomatocytosis has been ruled out (see <a href="#epb42-spherocytosis.Differential_Diagnos">Differential Diagnosis</a>). Note: Total splenectomy is not recommended for children younger than age five years even if the child requires frequent transfusions for moderately severe HS (which is rare in EPB42-HS).</p><p>Although splenectomy is curative, it entails potential long-term increased risk for life-threatening infection and, thus, should not be undertaken before the risks and benefits have been fully weighed [<a class="bk_pop" href="#epb42-spherocytosis.REF.casale.2011.627">Casale &#x00026; Perrotta 2011</a>].</p><p>Ideally, the following immunizations should be completed before splenectomy:</p><ul><li class="half_rhythm"><div>Immunizations for <i>Streptococcus pneumoniae</i> with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) and for <i>N meningitidis</i> with a meningococcal conjugate vaccine against the serogroups A, C, W, and Y (MenACWY) at least two weeks before splenectomy. A two-dose primary series of MenACWY is recommended 8-12 weeks apart [<a class="bk_pop" href="#epb42-spherocytosis.REF.committee_on_infectious_diseases.2011.1213">Committee on Infectious Diseases 2011</a>].</div></li><li class="half_rhythm"><div>Prevnar-13<sup>&#x000ae;</sup> and <i>H influenzae type b</i> vaccines during infancy per general pediatric immunization guidelines</div></li></ul><p>The incidence of post-splenectomy sepsis varies among studies. Although low overall, the risk for sepsis, a life-threatening complication, is higher than in the general population [<a class="bk_pop" href="#epb42-spherocytosis.REF.iolascon.1998.240">Iolascon et al 1998</a>]. To reduce the risk of infection post splenectomy, the following are recommended:</p><ul><li class="half_rhythm"><div>Give booster vaccination for PPSV23 five years after the first dose. No more than two PPSV23 doses are recommended [<a class="bk_pop" href="#epb42-spherocytosis.REF.nuorti.2010.1">Nuorti et al 2010</a>].</div></li><li class="half_rhythm"><div>Give booster dose for meningococcal vaccine three years after the primary series if the primary two-dose series was given between ages two and six years and every five years for persons whose two-dose primary series or booster dose was given at age seven years or older [<a class="bk_pop" href="#epb42-spherocytosis.REF.cohn.2013.1">Cohn et al 2013</a>].</div></li><li class="half_rhythm"><div>Serogroup B meningococcal vaccines are recommended for people age ten years and older with history of splenectomy.</div></li></ul><p>Controversy exists regarding the duration of use of antibiotics for prophylaxis post-splenectomy: some hematologists recommend prophylactic antibiotics for the first three years post splenectomy and others for life [<a class="bk_pop" href="#epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</a>]. The antibiotics recommended are penicillin V-K 250 mg twice daily or erythromycin for those allergic to penicillin.</p><p>In any case, an individual who has undergone splenectomy needs immediate medical attention for fever and prompt use of IV antibiotics with good coverage for encapsulated organisms (typically ceftriaxone in doses adequate to treat meningitis: 100 mg/kg/day up to 2 g/day in single daily dose).</p><p><b>Partial splenectomy</b> appears to be associated with a lesser risk for post-splenectomy sepsis and a sustained decrease (although not elimination) of hemolysis and may be preferable for young children if the surgeon is experienced in the procedure [<a class="bk_pop" href="#epb42-spherocytosis.REF.badermeunier.2001.399">Bader-Meunier et al 2001</a>]. An ongoing prospective observation of more than 100 children in a <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> hemolytic anemia multi-institutional registry, who have undergone total or partial splenectomy, may elucidate better the risks and benefits of each procedure [<a class="bk_pop" href="#epb42-spherocytosis.REF.rice.2012.684">Rice et al 2012</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.rice.2015.187">Rice et al 2015</a>].</p><p>Antibiotic prophylaxis may be discontinued one year after partial splenectomy if immune splenic function is adequate as assessed by pit count (percentage of pitted or pocked red cells) or the uptake of radioactive colloid by the spleen [<a class="bk_pop" href="#epb42-spherocytosis.REF.eber.2004">Eber &#x00026; Lux 2004</a>].</p><p><b>Cholecystectomy</b></p><ul><li class="half_rhythm"><div>The gallbladder should be removed in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals undergoing splenectomy who have a history of cholelithiasis.</div></li><li class="half_rhythm"><div>In children who require cholecystectomy, concurrent splenectomy is not recommended automatically any more. The need for splenectomy should be assessed on a case-by-case basis and the indication of splenectomy justified independently [<a class="bk_pop" href="#epb42-spherocytosis.REF.boltonmaggs.2012">Bolton-Maggs et al 2012</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.ruparel.2014.433">Ruparel et al 2014</a>].</div></li></ul></div><div id="epb42-spherocytosis.Prevention_of_Primar"><h3>Prevention of Primary Manifestations</h3><p><b>Splenectomy</b> is rarely indicated in EPB42-HS, as disease severity is usually mild or moderate. Note: When indicated, splenectomy is curative; however, it can have potential life-threatening complications (see <a href="#epb42-spherocytosis.Treatment_of_Manifes">Treatment of Manifestations</a>). Note: Total splenectomy is not recommended for children younger than age five years even if the child requires frequent transfusions for moderately severe HS (which is rare in EPB42-HS).</p></div><div id="epb42-spherocytosis.Prevention_of_Second"><h3>Prevention of Secondary Complications</h3><p><b>Regular immunizations</b> are recommended as well as influenza vaccine annually to prevent infections that can precipitate hemolytic or aplastic crisis.</p><p><b>Iron overload</b> and its associated chronic organ failure are risks with any chronic hemolytic anemia especially if frequent transfusions are required.</p><ul><li class="half_rhythm"><div>Treatment with an iron chelator should be implemented, typically after about ten transfusions (which correlate to a serum ferritin concentration of approximately 1000 ng/mL).</div></li><li class="half_rhythm"><div>The effectiveness of chelation should be monitored by evaluation of liver iron by T<sub>2</sub>*-weighted MRI or FerriScan<sup>&#x000ae;</sup> so that the dose of iron chelator can be adjusted appropriately.</div></li></ul></div><div id="epb42-spherocytosis.Surveillance"><h3>Surveillance</h3><p>Neonates with HS require monitoring of serum bilirubin concentration during the first week of life so that treatment for hyperbilirubinemia can be instituted promptly to avoid complications such as kernicterus.</p><p>Infants with HS require monitoring in the first two to four months of life for significant anemia, which may require RBC transfusion</p><p>Those dependent on frequent transfusions require at least annual measurement of serum ferritin concentration.</p><p>If iron chelation is required secondary to frequent transfusions in children too young to undergo splenectomy, appropriate monitoring for toxicity and effectiveness of chelation treatment is necessary [<a class="bk_pop" href="#epb42-spherocytosis.REF.musallam.2013.64">Musallam et al 2013</a>].</p><p>When hemolysis is significant, ultrasound examination to evaluate for cholelithiasis is indicated by age ten to twelve years, and every five to ten years thereafter.</p></div><div id="epb42-spherocytosis.AgentsCircumstances"><h3>Agents/Circumstances to Avoid</h3><p>Any preparations containing iron should be avoided (see <a href="#epb42-spherocytosis.Treatment_of_Manifes">Treatment of Manifestations</a>).</p><p>Contact sports are not advisable in those with splenomegaly; of note, acute or excessive splenomegaly is a greater risk than chronic mild splenomegaly.</p></div><div id="epb42-spherocytosis.Evaluation_of_Relati"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to perform laboratory evaluation of the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> (CBC and reticulocyte count, blood smear, osmotic fragility or ektacytometry) and clarify the genetic status of apparently asymptomatic older and younger sibs of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of the <i>EPB42</i> pathogenic variants in the family in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p><ul><li class="half_rhythm"><div>Neonates require monitoring of serum bilirubin concentration during the first week of life so that treatment for hyperbilirubinemia can be instituted promptly to avoid complications such as kernicterus.</div></li><li class="half_rhythm"><div>Infants require monitoring in the first two to four months of life for significant anemia, which may require RBC transfusion and initiation of folate supplementation</div></li></ul><p>See <a href="#epb42-spherocytosis.Related_Genetic_Coun">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="epb42-spherocytosis.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Folic acid supplementation (800-1000 &#x000b5;g daily) is necessary in pregnant women with chronic hemolytic anemias such as EPB42-HS.</p><p>Monitoring for exacerbation of anemia with CBC and reticulocyte count is recommended in pregnant women with HS, as hemolytic crisis and persistent anemia have been reported during pregnancy, especially in women who have not undergone splenectomy [<a class="bk_pop" href="#epb42-spherocytosis.REF.pajor.1993.37">Pajor et al 1993</a>].</p></div><div id="epb42-spherocytosis.Therapies_Under_Inve"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="epb42-spherocytosis.Genetic_Counseling"><h2 id="_epb42-spherocytosis_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="epb42-spherocytosis.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p><i>EPB42</i>-related hereditary spherocytosis (EPB42-HS) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="epb42-spherocytosis.Risk_to_Family_Membe"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child are obligate heterozygotes (i.e., carriers of one <i>EPB42</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> The offspring of an individual with EPB42-HS are obligate heterozygotes (carriers) for an <i>EPB42</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of an <i>EPB42</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="epb42-spherocytosis.Carrier_Heterozygote"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>EPB42</i> pathogenic variants in the family.</p></div><div id="epb42-spherocytosis.Related_Genetic_Coun"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#epb42-spherocytosis.Evaluation_of_Relati">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="epb42-spherocytosis.Prenatal_Testing_and"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>EPB42</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for EPB42-HS are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="epb42-spherocytosis.Resources"><h2 id="_epb42-spherocytosis_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition/hereditary-spherocytosis" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Hereditary spherocytosis</a></div></li></ul></div><div id="epb42-spherocytosis.Molecular_Genetics"><h2 id="_epb42-spherocytosis_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="epb42-spherocytosis.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>EPB42-Related Hereditary Spherocytosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK190102/table/epb42-spherocytosis.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epb42-spherocytosis.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/2038" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>EPB42</i></a></td><td headers="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=2038" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">15q15<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P16452" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Erythrocyte membrane protein band 4.2</a></td><td headers="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/EPB42" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EPB42 database</a></td><td headers="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=EPB42" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EPB42</a></td><td headers="hd_b_epb42-spherocytosis.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=EPB42[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EPB42</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="epb42-spherocytosis.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="epb42-spherocytosis.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for EPB42-Related Hereditary Spherocytosis (<a href="/omim/177070,612690" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK190102/table/epb42-spherocytosis.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epb42-spherocytosis.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/177070" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">177070</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PROTEIN 4.2, ERYTHROCYTIC; EPB42</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/612690" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">612690</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SPHEROCYTOSIS, TYPE 5; SPH5</td></tr></tbody></table></div></div><div id="epb42-spherocytosis.Molecular_Genetic_Pa"><h3>Molecular Genetic Pathogenesis</h3><p>Erythrocyte membrane protein band 4.2 (also known as protein 4.2), encoded by <i>EPB42,</i> is a major component of the red blood cell cytoskeleton and maintains the stability and flexibility of red cells through interactions with other key RBC proteins, many of which (in their pathogenic forms) also cause hereditary spherocytosis.</p><p>Protein 4.2 is a part of the ankyrin-band 3 complex, connecting band 3 protein (encoded by <i>SLC4A1</i>; see <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.classification_of/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTclassificationof" rid-ob="figobepb42spherocytosisTclassificationof">Table 3</a>, SPH4<i>)</i> with the CD47 and Rhesus protein complex antigens. Protein 4.2 supports physical associations between the cytoskeleton and the membrane lipid bilayer [<a class="bk_pop" href="#epb42-spherocytosis.REF.bruce.2003.4180">Bruce et al 2003</a>].</p><p>Protein 4.2 interacts with spectrin, a tetramer comprising an alpha-subunit (see <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.classification_of/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTclassificationof" rid-ob="figobepb42spherocytosisTclassificationof">Table 3</a>, SPH3) and beta-subunit (see <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.classification_of/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTclassificationof" rid-ob="figobepb42spherocytosisTclassificationof">Table 3</a>, SPH2), which is the largest protein in the RBC cytoskeleton [<a class="bk_pop" href="#epb42-spherocytosis.REF.mandal.2002.841">Mandal et al 2002</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.korsgren.2010.4757">Korsgren et al 2010</a>].</p><p><b>Gene structure.</b>
<i>EPB42</i> (previously known as <i>ELB42</i>) spans approximately 23 kb of <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> DNA. The longer transcript isoform (<a href="/nuccore/NM_000119.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000119.2</a>) has 2554 bp and 13 exons. Alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> produces a shorter transcript variant (<a href="/nuccore/NM_001114134.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_001114134.1</a>) excluding the last 90 nucleotides of <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 1. For a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information, see <a href="/books/NBK190102/#epb42-spherocytosis.molgen.TA">Table A</a>, <b>Gene</b>.</p><p><b>Pathogenic variants.</b> To date, at least 13 distinct <i>EPB42</i> pathogenic variants have been described, including <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, frameshift, and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants and small deletions. More than 50% of the identified pathogenic variants have been in the Japanese population [<a class="bk_pop" href="#epb42-spherocytosis.REF.bouhassira.1992.1846">Bouhassira et al 1992</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.yawata.2000.118">Yawata et al 2000</a>]. Affected individuals from Europe [<a class="bk_pop" href="#epb42-spherocytosis.REF.perrotta.1999.660">Perrotta et al 1999</a>, <a class="bk_pop" href="#epb42-spherocytosis.REF.van_den_akker.2010.1278">van den Akker et al 2010</a>] and North America [<a class="bk_pop" href="#epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</a>] have also been identified.</p><p>The p.Ala142Thr variant has been observed in a <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state in <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals. While this variant has a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> frequency of approximately 3% in persons of Japanese ancestry, it was also found in an affected individual from central Italy who had no Japanese ancestry [<a class="bk_pop" href="#epb42-spherocytosis.REF.perrotta.1999.660">Perrotta et al 1999</a>]. Although the frequency in the Japanese population is likely explained by a <a class="def" href="/books/n/gene/glossary/def-item/founder-effect/">founder effect</a>, the apparent random occurrence of this variant in another population may be explained by the fact that the G&#x0003e;A transition occurs within a CpG site on the antisense DNA strand [<a class="bk_pop" href="#epb42-spherocytosis.REF.elango.2008.e1000015">Elango et al 2008</a>].</p><div id="epb42-spherocytosis.T.epb42_pathogenic_v" class="table"><h3><span class="label">Table 4. </span></h3><div class="caption"><p><i>EPB42</i> Pathogenic Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__epb42-spherocytosis.T.epb42_pathogenic_v_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change<br />(Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.424G&#x0003e;A</td><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala142Thr<br />(4.2 Nippon)</td><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_3" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000119.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000119<wbr style="display:inline-block"></wbr>​.2</a><br /><a href="/protein/NP_000110.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000110<wbr style="display:inline-block"></wbr>​.2</a></td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.523G&#x0003e;T</td><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Asp175Tyr<br />(4.2 Komatsu)</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.920C&#x0003e;T</td><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr307Ile<br />(4.2 Cincinnati)</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.929G&#x0003e;A</td><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg310Gln<br />(4.2 Tozeur)</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.949C&#x0003e;T</td><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg317Cys<br />(4.2 Shiga)</td></tr><tr><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.950delG</td><td headers="hd_h_epb42-spherocytosis.T.epb42_pathogenic_v_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Frameshift<br />(4.2 Nancy)</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="epb42-spherocytosis.TF.4.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The long and short <i>EPB42</i> transcript variants encode the two protein 4.2 <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>: the 74-kd minor isoform of 721 amino acids (<a href="/protein/NP_000110.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000110.2</a>) and the 72-kd major isoform of 691 amino acids (<a href="/protein/NP_001107606.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_001107606.1</a>). Although homologous to transglutaminases, protein 4.2 lacks two of the catalytic triad residues required for transglutaminase activity, and thus is an enzymatically inactive protein [<a class="bk_pop" href="#epb42-spherocytosis.REF.toye.2005.4088">Toye et al 2005</a>].</p><p>Protein 4.2 is a major component of the red blood cell cytoskeleton and maintains the stability and flexibility of red cells through interactions with other key RBC proteins, many of which (in their pathogenic forms) also cause hereditary spherocytosis (see <a href="#epb42-spherocytosis.Molecular_Genetic_Pa">Molecular Genetic Pathogenesis</a> and <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.classification_of/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTclassificationof" rid-ob="figobepb42spherocytosisTclassificationof">Table 3</a>).</p><p>Aggravation of hemolysis during the neonatal period has been attributed to the presence of fetal hemoglobin, which has poor affinity for 2,3-diphosphoglycerate (2,3-DPG), resulting in increased free intracellular 2,3-DPG that destabilizes the spectrin-protein 4.1 interactions and intensifies hemolysis [<a class="bk_pop" href="#epb42-spherocytosis.REF.mentzer.1987.943">Mentzer et al 1987</a>].</p><p>Protein 4.2 interacts with its binding partners in the RBC cytoskeleton via specific domains. Protein 4.2 amino acid residues 187-211 of the long isoform <a href="https://www.ncbi.nlm.nih.gov/protein/NP_000110.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000110.2</a> have been shown to mediate binding to ankyrin (see <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.classification_of/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTclassificationof" rid-ob="figobepb42spherocytosisTclassificationof">Table 3</a>, SPH1) and band 3, bridging these two proteins [<a class="bk_pop" href="#epb42-spherocytosis.REF.su.2006.159">Su et al 2006</a>] and linking band 3 and the lipid bilayer with the cytoskeletal scaffold.</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> More than half of the identified <i>EPB42</i> pathogenic variants are predicted to result in complete loss of protein, which is presumed to be the mechanism of pathogenesis.</p><p>At least six distinct pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants have been observed. Functional analyses include the following:</p><ul><li class="half_rhythm"><div>In vitro binding studies of the <i>EPB42</i> alleles encoding <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Arg310Gln</a> and <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Asp175Tyr</a> demonstrated altered binding of protein 4.2 to band 3 [<a class="bk_pop" href="#epb42-spherocytosis.REF.toye.2005.4088">Toye et al 2005</a>].</div></li><li class="half_rhythm"><div>The <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Thr307Ile</a> [<a class="bk_pop" href="#epb42-spherocytosis.REF.hammill.2011.780">Hammill et al 2011</a>] and p.Arg317Cys [<a class="bk_pop" href="#epb42-spherocytosis.REF.kanzaki.1995.165">Kanzaki et al 1995</a>] pathogenic variants within the putative band 3 binding <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> lead to complete absence of protein 4.2, presumably due to proteolysis before incorporation into the membrane.</div></li><li class="half_rhythm"><div>In in vitro studies the <a class="figpopup" href="/books/NBK190102/table/epb42-spherocytosis.T.epb42_pathogenic_v/?report=objectonly" target="object" rid-figpopup="figepb42spherocytosisTepb42pathogenicv" rid-ob="figobepb42spherocytosisTepb42pathogenicv">p.Ala142Thr</a> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> binds band 3 normally, suggesting that this <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> causes 4.2 deficiency independent of band 3 [<a class="bk_pop" href="#epb42-spherocytosis.REF.toye.2005.4088">Toye et al 2005</a>]. The p.Ala142Thr variant in the <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> state (observed in four unrelated Japanese individuals) results in RBC ghost membranes that are almost completely deficient for protein 4.2 [<a class="bk_pop" href="#epb42-spherocytosis.REF.bouhassira.1992.1846">Bouhassira et al 1992</a>].</div></li></ul><p>Of note, although band 3 levels in protein 4.2-deficient RBCs are not altered, the extractability and lateral diffusion of band 3 are significantly increased [<a class="bk_pop" href="#epb42-spherocytosis.REF.rybicki.1996.2745">Rybicki et al 1996</a>].</p></div></div><div id="epb42-spherocytosis.References"><h2 id="_epb42-spherocytosis_References_">References</h2><div id="epb42-spherocytosis.Published_Guidelines"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.boltonmaggs.2012">Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ. Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. Available <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2011.08921.x/full" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2012. Accessed 4-17-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.boltonmaggs.2004">Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ. Guidelines for the diagnosis and management of hereditary spherocytosis. Available <a href="http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2141.2004.05052.x/full" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2004. Accessed 4-17-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.eber.2004">Eber S, Lux SE. Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer. 2004. [<a href="/pubmed/15071790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15071790</span></a>]</div></li></ul></div><div id="epb42-spherocytosis.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.badermeunier.2001.399">Bader-Meunier B, Gauthier F, Archambaud F, Cynober T, Mielot F, Dommergues JP, Warszawski J, Mohandas N, Tchernia G. Long-term evaluation of the beneficial effect of subtotal splenectomy for management of hereditary spherocytosis. <span><span class="ref-journal">Blood. </span>2001;<span class="ref-vol">97</span>:399–403.</span> [<a href="/pubmed/11154215" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11154215</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.beauchampnicoud.2000.19">Beauchamp-Nicoud A, Morle L, Lutz HU, Stammler P, Agulles O, Petermann-Khder R, Iolascon A, Perrotta S, Cynober T, Tchernia G, Delaunay J, Baudin-Creuza V. Heavy transfusions and presence of an anti-protein 4.2 antibody in 4. 2(-) hereditary spherocytosis (949delG). <span><span class="ref-journal">Haematologica. </span>2000;<span class="ref-vol">85</span>:19–24.</span> [<a href="/pubmed/10629586" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10629586</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.boltonmaggs.2012.37">Bolton-Maggs PH, Langer JC, Iolascon A, Tittensor P, King MJ. Guidelines for the diagnosis and management of hereditary spherocytosis--2011 update. <span><span class="ref-journal">Br J Haematol. </span>2012;<span class="ref-vol">156</span>:37–49.</span> [<a href="/pubmed/22055020" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22055020</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.bouhassira.1992.1846">Bouhassira EE, Schwartz RS, Yawata Y, Ata K, Kanzaki A, Qiu JJ, Nagel RL, Rybicki AC. An alanine-to-threonine substitution in protein 4.2 cDNA is associated with a Japanese form of hereditary hemolytic anemia (protein 4.2NIPPON). <span><span class="ref-journal">Blood. </span>1992;<span class="ref-vol">79</span>:1846–54.</span> [<a href="/pubmed/1558976" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1558976</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.bruce.2003.4180">Bruce LJ, Beckmann R, Ribeiro ML, Peters LL, Chasis JA, Delaunay J, Mohandas N, Anstee DJ, Tanner MJ. A band 3-based macrocomplex of integral and peripheral proteins in the RBC membrane. <span><span class="ref-journal">Blood. </span>2003;<span class="ref-vol">101</span>:4180–8.</span> [<a href="/pubmed/12531814" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12531814</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.casale.2011.627">Casale M, Perrotta S. Splenectomy for hereditary spherocytosis: complete, partial or not at all? <span><span class="ref-journal">Expert Rev Hematol. </span>2011;<span class="ref-vol">4</span>:627–35.</span> [<a href="/pubmed/22077527" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22077527</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.clark.1983.899">Clark MR, Mohandas N, Shohet SB. Osmotic gradient ektacytometry: comprehensive characterization of red cell volume and surface maintenance. <span><span class="ref-journal">Blood. </span>1983;<span class="ref-vol">61</span>:899–910.</span> [<a href="/pubmed/6831052" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6831052</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.cohn.2013.1">Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, et al.  Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). <span><span class="ref-journal">MMWR Recomm Rep. </span>2013;<span class="ref-vol">62</span>:1–28.</span> [<a href="/pubmed/23515099" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23515099</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.committee_on_infectious_diseases.2011.1213">Committee on Infectious Diseases.  Meningococcal conjugate vaccines policy update: booster dose recommendations. <span><span class="ref-journal">Pediatrics. </span>2011;<span class="ref-vol">128</span>:1213–8.</span> [<a href="/pubmed/22123893" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22123893</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.eber.2004.118">Eber S, Lux SE. Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer. <span><span class="ref-journal">Semin Hematol. </span>2004;<span class="ref-vol">41</span>:118–41.</span> [<a href="/pubmed/15071790" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15071790</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.elango.2008.e1000015">Elango N, Kim SH, Vigoda E, Yi SV. Mutations of different molecular origins exhibit contrasting patterns of regional substitution rate variation. <span><span class="ref-journal">PLoS Comput Biol. </span>2008;<span class="ref-vol">4</span>:e1000015.</span> [<a href="/pmc/articles/PMC2265638/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2265638</span></a>] [<a href="/pubmed/18463707" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18463707</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.hammill.2011.780">Hammill AM, Risinger MA, Joiner CH, Keddache M, Kalfa TA. Compound heterozygosity for two novel mutations in the erythrocyte protein 4.2 gene causing spherocytosis in a Caucasian patient. <span><span class="ref-journal">Br J Haematol. </span>2011;<span class="ref-vol">152</span>:780–3.</span> [<a href="/pmc/articles/PMC3105174/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3105174</span></a>] [<a href="/pubmed/21275958" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21275958</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.hayette.1995.250">Hayette S, Dhermy D, dos Santos ME, Bozon M, Drenckhahn D, Alloisio N, Texier P, Delaunay J, Morl&#x000e9; L. A deletional frameshift mutation in protein 4.2 gene (allele 4.2 Lisboa) associated with hereditary hemolytic anemia. <span><span class="ref-journal">Blood. </span>1995;<span class="ref-vol">85</span>:250–6.</span> [<a href="/pubmed/7803799" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7803799</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.iolascon.1998.240">Iolascon A, Miraglia del Giudice E, Perrotta S, Alloisio N, Morle L, Delaunay J. Hereditary spherocytosis: from clinical to molecular defects. <span><span class="ref-journal">Haematologica. </span>1998;<span class="ref-vol">83</span>:240–57.</span> [<a href="/pubmed/9573679" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9573679</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.kanzaki.1997.522">Kanzaki A, Hayette S, Morle L, Inoue F, Matsuyama R, Inoue T, Yawata A, Wada H, Vallier A, Alloisio N, Yawata Y, Delaunay J. Total absence of protein 4.2 and partial deficiency of band 3 in hereditary spherocytosis. <span><span class="ref-journal">Br J Haematol. </span>1997;<span class="ref-vol">99</span>:522–30.</span> [<a href="/pubmed/9401060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9401060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.kanzaki.1995.165">Kanzaki A, Yawata Y, Yawata A, Inoue T, Okamoto N, Wada H, Harano T, Harano K, Wilmotte R, Hayette S. Band 4.2 Komatsu: 523 GAT--&#x0003e;TAT (175 Asp--&#x0003e;Tyr) in exon 4 of the band 4.2 gene associated with total deficiency of band 4.2, hemolytic anemia with ovalostomatocytosis and marked disruption of the cytoskeletal network. <span><span class="ref-journal">Int J Hematol. </span>1995;<span class="ref-vol">61</span>:165–78.</span> [<a href="/pubmed/8547605" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8547605</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.korsgren.2010.4757">Korsgren C, Peters LL, Lux SE. Protein 4.2 binds to the carboxyl-terminal EF-hands of erythroid alpha-spectrin in a calcium- and calmodulin-dependent manner. <span><span class="ref-journal">J Biol Chem. </span>2010;<span class="ref-vol">285</span>:4757–70.</span> [<a href="/pmc/articles/PMC2836081/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2836081</span></a>] [<a href="/pubmed/20007969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20007969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.mandal.2002.841">Mandal D, Moitra PK, Basu J. Mapping of a spectrin-binding domain of human erythrocyte membrane protein 4.2. <span><span class="ref-journal">Biochem J. </span>2002;<span class="ref-vol">364</span>:841–7.</span> [<a href="/pmc/articles/PMC1222634/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1222634</span></a>] [<a href="/pubmed/12049649" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12049649</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.mentzer.1987.943">Mentzer WC Jr, Iarocci TA, Mohandas N, Lane PA, Smith B, Lazerson J, Hays T. Modulation of erythrocyte membrane mechanical stability by 2,3-diphosphoglycerate in the neonatal poikilocytosis/elliptocytosis syndrome. <span><span class="ref-journal">J Clin Invest. </span>1987;<span class="ref-vol">79</span>:943–9.</span> [<a href="/pmc/articles/PMC424243/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC424243</span></a>] [<a href="/pubmed/3818955" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 3818955</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.mohandas.1982.768">Mohandas N, Clark MR, Health BP, Rossi M, Wolfe LC, Lux SE, Shohet SB. A technique to detect reduced mechanical stability of red cell membranes: relevance to elliptocytic disorders. <span><span class="ref-journal">Blood. </span>1982;<span class="ref-vol">59</span>:768–74.</span> [<a href="/pubmed/7059678" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7059678</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.musallam.2013.64">Musallam KM, Angastiniotis M, Eleftheriou A, Porter JB. Cross-talk between available guidelines for the management of patients with beta-thalassemia major. <span><span class="ref-journal">Acta Haematol. </span>2013;<span class="ref-vol">130</span>:64–73.</span> [<a href="/pubmed/23485589" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23485589</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.nuorti.2010.1">Nuorti JP, Whitney CG, et al.  Prevention of pneumococcal disease among infants and children -- use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP). <span><span class="ref-journal">MMWR Recomm Rep. </span>2010;<span class="ref-vol">59</span>:1–18.</span> [<a href="/pubmed/21150868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21150868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.pajor.1993.37">Pajor A, Lehoczky D, Szakacs Z. Pregnancy and hereditary spherocytosis. Report of 8 patients and a review. <span><span class="ref-journal">Arch Gynecol Obstet. </span>1993;<span class="ref-vol">253</span>:37–42.</span> [<a href="/pubmed/8328819" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8328819</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.perrotta.2008.1411">Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. <span><span class="ref-journal">Lancet. </span>2008;<span class="ref-vol">372</span>:1411–26.</span> [<a href="/pubmed/18940465" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18940465</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.perrotta.1999.660">Perrotta S, Iolascon A, Polito R, d'Urzo G, Conte ML, Miraglia del Giudice E. 4.2 Nippon mutation in a non-Japanese patient with hereditary spherocytosis. <span><span class="ref-journal">Haematologica. </span>1999;<span class="ref-vol">84</span>:660–2.</span> [<a href="/pubmed/10406914" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10406914</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.rice.2012.684">Rice HE, Crary SE, Langer JC, Kemper AR. Consortium ftSiCHA. Comparative effectiveness of different types of splenectomy for children with congenital hemolytic anemias. <span><span class="ref-journal">J Pediatr. </span>2012;<span class="ref-vol">160</span>:684–9.e13.</span> [<a href="/pubmed/22050869" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22050869</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.rice.2015.187">Rice HE, Englum BR, Rothman J, Leonard S, Reiter A, Thornburg C, Brindle M, Wright N, Heeney MM, Smithers C, Brown RL, Kalfa T, Langer JC, Cada M, Oldham KT, Scott JP, St Peter S, Sharma M, Davidoff AM, Nottage K, Bernabe K, Wilson DB, Dutta S, Glader B, Crary SE, Dassinger MS, Dunbar L, Islam S, Kumar M, Rescorla F, Bruch S, Campbell A, Austin M, Sidonio R, Blakely ML, et al.  Clinical outcomes of splenectomy in children: report of the splenectomy in congenital hemolytic anemia registry. <span><span class="ref-journal">Am J Hematol. </span>2015;<span class="ref-vol">90</span>:187–92.</span> [<a href="/pmc/articles/PMC4333061/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4333061</span></a>] [<a href="/pubmed/25382665" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25382665</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.ruparel.2014.433">Ruparel RK, Bogert JN, Moir CR, Ishitani MB, Khan SP, Rodriguez V, Zarroug AE. Synchronous splenectomy during cholecystectomy for hereditary spherocytosis: is it really necessary? <span><span class="ref-journal">J Pediatr Surg. </span>2014;<span class="ref-vol">49</span>:433–5.</span> [<a href="/pubmed/24650472" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24650472</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.rybicki.1996.2745">Rybicki AC, Schwartz RS, Hustedt EJ, Cobb CE. Increased rotational mobility and extractability of band 3 from protein 4.2-deficient erythrocyte membranes: evidence of a role for protein 4.2 in strengthening the band 3-cytoskeleton linkage. <span><span class="ref-journal">Blood. </span>1996;<span class="ref-vol">88</span>:2745–53.</span> [<a href="/pubmed/8839871" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8839871</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.satchwell.2009.201">Satchwell TJ, Shoemark DK, Sessions RB, Toye AM. Protein 4.2: a complex linker. <span><span class="ref-journal">Blood Cells Mol Dis. </span>2009;<span class="ref-vol">42</span>:201–10.</span> [<a href="/pubmed/19269200" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19269200</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.su.2006.159">Su Y, Ding Y, Jiang M, Jiang W, Hu X, Zhang Z. Associations of protein 4.2 with band 3 and ankyrin. <span><span class="ref-journal">Molecular and cellular biochemistry. </span>2006;<span class="ref-vol">289</span>:159–66.</span> [<a href="/pubmed/16718373" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16718373</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.takaoka.1994.527">Takaoka Y, Ideguchi H, Matsuda M, Sakamoto N, Takeuchi T, Fukumaki Y. A novel mutation in the erythrocyte protein 4.2 gene of Japanese patients with hereditary spherocytosis (protein 4.2 Fukuoka). <span><span class="ref-journal">Br J Haematol. </span>1994;<span class="ref-vol">88</span>:527–33.</span> [<a href="/pubmed/7819064" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7819064</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.toye.2005.4088">Toye AM, Ghosh S, Young MT, Jones GK, Sessions RB, Ramauge M, Leclerc P, Basu J, Delaunay J, Tanner MJ. Protein-4.2 association with band 3 (AE1, SLCA4) in Xenopus oocytes: effects of three natural protein-4.2 mutations associated with hemolytic anemia. <span><span class="ref-journal">Blood. </span>2005;<span class="ref-vol">105</span>:4088–95.</span> [<a href="/pubmed/15692067" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15692067</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.toye.2008.5380">Toye AM, Williamson RC, Khanfar M, Bader-Meunier B, Cynober T, Thibault M, Tchernia G, Dechaux M, Delaunay J, Bruce LJ. Band 3 Courcouronnes (Ser667Phe): a trafficking mutant differentially rescued by wild-type band 3 and glycophorin A. <span><span class="ref-journal">Blood. </span>2008;<span class="ref-vol">111</span>:5380–9.</span> [<a href="/pmc/articles/PMC2605348/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2605348</span></a>] [<a href="/pubmed/18174378" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18174378</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.van_den_akker.2010.1278">van den Akker E, Satchwell TJ, Pellegrin S, Flatt JF, Maigre M, Daniels G, Delaunay J, Bruce LJ, Toye AM. Investigating the key membrane protein changes during in vitro erythropoiesis of protein 4.2 (-) cells (mutations Chartres 1 and 2). <span><span class="ref-journal">Haematologica. </span>2010;<span class="ref-vol">95</span>:1278–86.</span> [<a href="/pmc/articles/PMC2913075/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2913075</span></a>] [<a href="/pubmed/20179084" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20179084</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.yawata.1994.131">Yawata Y. Red cell membrane protein band 4.2: phenotypic, genetic and electron microscopic aspects. <span><span class="ref-journal">Biochim Biophys Acta. </span>1994;<span class="ref-vol">1204</span>:131–48.</span> [<a href="/pubmed/8142452" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8142452</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.yawata.2000.118">Yawata Y, Kanzaki A, Yawata A, Doerfler W, Ozcan R, Eber SW. Characteristic features of the genotype and phenotype of hereditary spherocytosis in the Japanese population. <span><span class="ref-journal">Int J Hematol. </span>2000;<span class="ref-vol">71</span>:118–35.</span> [<a href="/pubmed/10745622" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10745622</span></a>]</div></li></ul></div><div id="epb42-spherocytosis.Suggested_Reading"><h3>Suggested Reading</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.cohen.1993.119">Cohen CM, Dotimas E, Korsgren C. Human erythrocyte membrane protein band 4.2 (pallidin). <span><span class="ref-journal">Semin Hematol. </span>1993;<span class="ref-vol">30</span>:119–37.</span> [<a href="/pubmed/8480187" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8480187</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.dotimas.1993.19">Dotimas E, Speicher DW. GuptaRoy B, Cohen CM. Structural domain mapping and phosphorylation of human erythrocyte pallidin (band 4.2). <span><span class="ref-journal">Biochim Biophys Acta. </span>1993;<span class="ref-vol">1148</span>:19–29.</span> [<a href="/pubmed/8499466" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8499466</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="epb42-spherocytosis.REF.korsgren.1988.10212">Korsgren C, Cohen CM. Associations of human erythrocyte band 4.2. Binding to ankyrin and to the cytoplasmic domain of band 3. <span><span class="ref-journal">J Biol Chem. </span>1988;<span class="ref-vol">263</span>:10212–8.</span> [<a href="/pubmed/2968981" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2968981</span></a>]</div></li></ul></div><div id="epb42-spherocytosis.Author_Notes"><h3>Author Notes</h3><p><a href="http://www.cincinnatichildrens.org/bio/k/theodosia-kalfa/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Theodosia Kalfa, MD, PhD</a></p><p><a href="http://www.cincinnatichildrens.org/research/divisions/h/hematology/labs/kalfa/default/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Kalfa Lab</a></p></div><div id="epb42-spherocytosis.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>10 November 2016 (ma) Comprehensive update posted live</div></li><li class="half_rhythm"><div>13 March 2014 (me) Review posted live</div></li><li class="half_rhythm"><div>20 October 2013 (tk) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK190102</span><span class="label">PMID: <a href="/pubmed/24624460" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">24624460</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/cyclic-n/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/exosc3-pc-hypo-p/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK190102&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK190102/?report=reader">PubReader</a></li><li><a href="/books/NBK190102/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK190102" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK190102" style="display:none" title="Cite this Page"><div class="bk_tt">Kalfa TA, Connor JA, Begtrup AH. EPB42-Related Hereditary Spherocytosis. 2014 Mar 13 [Updated 2016 Nov 10]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK190102/pdf/Bookshelf_NBK190102.pdf">PDF version of this page</a> (542K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#epb42-spherocytosis.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#epb42-spherocytosis.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#epb42-spherocytosis.Clinical_Characteris" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#epb42-spherocytosis.Genetically_Related" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#epb42-spherocytosis.Differential_Diagnos" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#epb42-spherocytosis.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#epb42-spherocytosis.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#epb42-spherocytosis.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#epb42-spherocytosis.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#epb42-spherocytosis.References" ref="log$=inpage&amp;link_id=inpage">References</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=2038[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">EPB42</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=3075988" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=3075988" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=3075988" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=3075988" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301599" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Beta-Thalassemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Origa R. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301608" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alpha-Thalassemia</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alpha-Thalassemia<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Origa R, Moi P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301551" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sickle Cell Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Sickle Cell Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Bender MA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301446" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pastores GM, Hughes DA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=24624460" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=24624460" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e04105edd21425a25912271">EPB42-Related Hereditary Spherocytosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">EPB42-Related Hereditary Spherocytosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:43:58-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE88EC31E040CD5100000000017D008F&amp;ncbi_session=CE88EC31E04105D1_0381SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK190102%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK190102&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK190102/&amp;ncbi_pagename=EPB42-Related Hereditary Spherocytosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88EC31E04105D1_0381SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>